Two Sigma Advisers
AKRO

Two Sigma Advisers’s Akero Therapeutics AKRO Stock Holding History

Two Sigma Advisers’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-41,100
Closed -$1.14M – 2371
2024
Q4 		$1.14M Buy
41,100
+27,200
+196% +$824K ﹤0.01% 1396
2024
Q3 		$399K Sell
13,900
-4,200
-23% -$109K ﹤0.01% 1797
2024
Q2 		$425K Buy
+18,100
New +$387K ﹤0.01% 1952
2023
Q2 		– Sell
-18,200
Closed -$696K – 2372
2023
Q1 		$696K Sell
18,200
-2,900
-14% -$129K ﹤0.01% 1804
2022
Q4 		$1.16M Buy
+21,100
New +$904K ﹤0.01% 1509
2022
Q3 		– Sell
-22,200
Closed -$210K – 2529
2022
Q2 		$210K Sell
22,200
-2,400
-10% -$25K ﹤0.01% 2258
2022
Q1 		$349K Sell
24,600
-14,400
-37% -$252K ﹤0.01% 2158
2021
Q4 		$825K Sell
39,000
-41,400
-51% -$918K ﹤0.01% 1659
2021
Q3 		$1.8M Sell
80,400
-59,900
-43% -$1.36M ﹤0.01% 1316
2021
Q2 		$3.48M Sell
140,300
-29,400
-17% -$826K 0.01% 1034
2021
Q1 		$4.92M Buy
169,700
+35,900
+27% +$1.09M 0.01% 857
2020
Q4 		$3.45M Buy
133,800
+121,900
+1,024% +$3.39M 0.01% 981
2020
Q3 		$366K Buy
+11,900
New +$416K ﹤0.01% 1939

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Advisers's AKRO Position: Q1 2025 in Review

Two Sigma Advisers sold out of Akero Therapeutics (AKRO) in Q1 2025, closing a stake of 41,100 shares — an estimated $1.14M sold.

Two Sigma Advisers first reported a position in AKRO in Q3 2020 and held it in 13 quarters. The position peaked at $4.92M in Q1 2021. 240 funds tracked by Wall St. Rank hold AKRO as of Q1 2025.

  • Two Sigma Advisers reported no remaining Akero Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 41,100 Akero Therapeutics shares in Q1 2025, an estimated $1.14M.
  • Two Sigma Advisers first reported a position in Akero Therapeutics in Q3 2020 and held it in 13 quarters.
  • Two Sigma Advisers's Akero Therapeutics position peaked at $4.92M in Q1 2021.
  • 240 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2025.

Based on Two Sigma Advisers's 13F filing for Q1 2025, filed 15 May 2025.